433 related articles for article (PubMed ID: 21509680)
1. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
Klein B; Seckinger A; Moehler T; Hose D
Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
[TBL] [Abstract][Full Text] [Related]
2. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
3. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
4. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.
Hewett DR; Vandyke K; Lawrence DM; Friend N; Noll JE; Geoghegan JM; Croucher PI; Zannettino ACW
Neoplasia; 2017 Dec; 19(12):972-981. PubMed ID: 29091798
[TBL] [Abstract][Full Text] [Related]
5. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis.
Bueno C; Lopes LF; Greaves M; Menendez P
Exp Hematol; 2007 Oct; 35(10):1477-8. PubMed ID: 17681665
[No Abstract] [Full Text] [Related]
6. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Corso A; Ferretti E; Lazzarino M
Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in multiple myeloma.
Vacca A; Ria R; Reale A; Ribatti D
Chem Immunol Allergy; 2014; 99():180-96. PubMed ID: 24217610
[TBL] [Abstract][Full Text] [Related]
8. The microenvironment and molecular biology of the multiple myeloma tumor.
Lemaire M; Deleu S; De Bruyne E; Van Valckenborgh E; Menu E; Vanderkerken K
Adv Cancer Res; 2011; 110():19-42. PubMed ID: 21704227
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
Ren Z; Spaargaren M; Pals ST
Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
[TBL] [Abstract][Full Text] [Related]
10. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
11. Targeting the bone marrow microenvironment in multiple myeloma.
Kawano Y; Moschetta M; Manier S; Glavey S; Görgün GT; Roccaro AM; Anderson KC; Ghobrial IM
Immunol Rev; 2015 Jan; 263(1):160-72. PubMed ID: 25510276
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.
Akhtar S; Ali TA; Faiyaz A; Khan OS; Raza SS; Kulinski M; Omri HE; Bhat AA; Uddin S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679860
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of myeloma.
Anderson KC; Carrasco RD
Annu Rev Pathol; 2011; 6():249-74. PubMed ID: 21261519
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and risk stratification in multiple myeloma.
van de Donk NW; Sonneveld P
Hematol Oncol Clin North Am; 2014 Oct; 28(5):791-813. PubMed ID: 25212883
[TBL] [Abstract][Full Text] [Related]
15. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.
Nair JR; Carlson LM; Koorella C; Rozanski CH; Byrne GE; Bergsagel PL; Shaughnessy JP; Boise LH; Chanan-Khan A; Lee KP
J Immunol; 2011 Aug; 187(3):1243-53. PubMed ID: 21715687
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma: biology of the disease.
Mahindra A; Hideshima T; Anderson KC
Blood Rev; 2010 Nov; 24 Suppl 1():S5-11. PubMed ID: 21126636
[TBL] [Abstract][Full Text] [Related]
17. Biology and bioinformatics of myeloma cell.
Abroun S; Saki N; Fakher R; Asghari F
Lab Hematol; 2012 Dec; 18(4):30-41. PubMed ID: 23253865
[TBL] [Abstract][Full Text] [Related]
18. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
[TBL] [Abstract][Full Text] [Related]
19. [Implication of bone marrow microenvironment in pathogenesis of multiple myeloma].
Fišerová B; Kubiczková L; Sevčíková S; Hájek R
Klin Onkol; 2012; 25(4):234-40. PubMed ID: 22920162
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow microenvironment and the progression of multiple myeloma.
Caligaris-Cappio F; Gregoretti MG; Merico F; Gottardi D; Ghia P; Parvis G; Bergui L
Leuk Lymphoma; 1992 Sep; 8(1-2):15-22. PubMed ID: 1493467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
